Renal Impairment
Conditions
Brief summary
Metabolic syndrome is a collection of conditions that affect at least three of the following five criteria: abdominal obesity, high blood pressure, high fasting glucose levels, high triglyceride levels, and low levels of high-density lipoprotein (HDL) cholesterol. Chronic kidney disease (CKD) is a common complication of metabolic syndrome, with an estimated prevalence of 13-40%. Early diagnosis of progressive conditions before the onset of reduced glomerular filtration rate (GFR) or albuminuria may be of clinical benefit but is not possible at present. Furthermore, the diagnosis and quantification of CKD in the context of metabolic syndrome is challenging due to the lack of reliable diagnostic biomarkers, and the current methods may not accurately reflect kidney function in patients with metabolic syndrome. Magnetic resonance imaging (MRI) has been sparsely explored as a potential tool to assess renal perfusion, oxygenation, and fibrosis. Multiparametric MRI (mpMRI) combines several different imaging techniques to provide a more comprehensive evaluation of tissue structure and function. These techniques hold promise for non-invasive assessment of kidney function, but their clinical utility is still largely experimental. Therefore, we aim to conduct an exploratory study to investigate the reliability, reproducibility as well as the validity of parameters for kidney function of multiparametric MRI as well as compare these parameters in between healthy patients and patients with metabolic syndrome.
Interventions
DIAGNOSTIC_TESTmpMRI
mpMRI
Sponsors
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Diagnosed metabolic syndrome
Exclusion criteria
* MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| T1 Time | 6 months | T1 relaxation time (MR characteristic of the human tissue, measured in ms) |
Countries
Switzerland
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Healthy Participants Healthy participants of different age groups | 46 |
| Total | 46 |
Baseline characteristics
| Characteristic | Healthy Participants | — |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | — |
| Age, Categorical >=65 years | 0 Participants | — |
| Age, Categorical Between 18 and 65 years | 46 Participants | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Serum Creatinine | 72 µmol/L STANDARD_DEVIATION 14.4 | — |
| Sex: Female, Male Female | 25 Participants | — |
| Sex: Female, Male Male | 21 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 46 |
| other Total, other adverse events | 0 / 46 |
| serious Total, serious adverse events | 0 / 46 |
Outcome results
Primary
T1 Time
T1 relaxation time (MR characteristic of the human tissue, measured in ms)
Time frame: 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Healthy participants | T1 Time | 1500 ms | Standard Deviation 15 |